Published in Curr Top Microbiol Immunol on January 01, 2013
Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer (2014) 1.67
APOBECs and virus restriction. Virology (2015) 1.27
Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio (2014) 1.15
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov (2015) 1.10
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer (2014) 1.07
What's the damage? The impact of pathogens on pathways that maintain host genome integrity. Cell Host Microbe (2014) 1.00
Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet (2014) 1.00
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res (2015) 0.93
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol (2014) 0.91
APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. Cell Rep (2016) 0.90
Crystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain. J Biol Chem (2015) 0.90
AID/APOBEC deaminases and cancer. Oncoscience (2015) 0.89
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators. Front Microbiol (2013) 0.88
The PKC/NF-κB Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers. Cancer Res (2015) 0.88
HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol (2015) 0.88
Origins of the endogenous and infectious laboratory mouse gammaretroviruses. Viruses (2014) 0.85
APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions. Cell Rep (2015) 0.85
Host restriction of murine gammaherpesvirus 68 replication by human APOBEC3 cytidine deaminases but not murine APOBEC3. Virology (2014) 0.84
Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-β/RUNX axis. Sci Adv (2015) 0.83
HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology (2015) 0.83
Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif. J Virol (2014) 0.83
APOBEC3F determinants of HIV-1 Vif sensitivity. J Virol (2014) 0.82
Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. Genome Med (2013) 0.81
Vif determines the requirement for CBF-β in APOBEC3 degradation. J Gen Virol (2014) 0.81
DNA Editing of LTR Retrotransposons Reveals the Impact of APOBECs on Vertebrate Genomes. Mol Biol Evol (2015) 0.80
Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase. BMC Microbiol (2014) 0.80
Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology (2013) 0.80
N-linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins. J Virol (2014) 0.80
A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection. J Virol (2015) 0.80
HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins. Proc Natl Acad Sci U S A (2016) 0.79
High-throughput mutagenesis reveals functional determinants for DNA targeting by activation-induced deaminase. Nucleic Acids Res (2014) 0.78
Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. Annu Rev Genet (2015) 0.78
1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure. J Mol Biol (2016) 0.78
Zinc enhancement of cytidine deaminase activity highlights a potential allosteric role of loop-3 in regulating APOBEC3 enzymes. Sci Rep (2015) 0.78
APOBEC3 Interference during Replication of Viral Genomes. Viruses (2015) 0.77
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res (2016) 0.77
Lack of Mutational Hot Spots during Decitabine-Mediated HIV-1 Mutagenesis. Antimicrob Agents Chemother (2015) 0.77
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clin Cancer Res (2016) 0.77
Origins and Evolution of tetherin, an Orphan Antiviral Gene. Cell Host Microbe (2016) 0.76
Species-specific differences in the ability of feline lentiviral Vif to degrade feline APOBEC3 proteins. Microbiol Immunol (2016) 0.76
APOBEC3 enzymes restrict marginal zone B cells. Eur J Immunol (2015) 0.76
Cellular HIV-1 inhibition by truncated old world primate APOBEC3A proteins lacking a complete deaminase domain. Virology (2014) 0.76
Putting an 'End' to HIV mRNAs: capping and polyadenylation as potential therapeutic targets. AIDS Res Ther (2013) 0.76
Retroviral vectors for analysis of viral mutagenesis and recombination. Viruses (2014) 0.76
Inhibition of APOBEC3G activity impedes double-stranded DNA repair. FEBS J (2015) 0.76
Avoidance of APOBEC3B-induced mutation by error-free lesion bypass. Nucleic Acids Res (2017) 0.76
Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women. PLoS One (2016) 0.75
Experimental evaluation of the zoonotic infection potency of simian retrovirus type 4 using humanized mouse model. Sci Rep (2015) 0.75
A naturally occurring bovine APOBEC3 confers resistance to bovine lentiviruses: implication for the co-evolution of bovids and their lentiviruses. Sci Rep (2016) 0.75
The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme. Sci Rep (2016) 0.75
The thermodynamics of Pr55Gag-RNA interaction regulate the assembly of HIV. PLoS Pathog (2017) 0.75
Risks at the DNA Replication Fork: Effects upon Carcinogenesis and Tumor Heterogeneity. Genes (Basel) (2017) 0.75
Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins. PLoS Pathog (2016) 0.75
APOBEC3A is Upregulated by Human Cytomegalovirus in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector. J Virol (2017) 0.75
Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra. J Mol Biol (2017) 0.75
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Mobile elements: drivers of genome evolution. Science (2004) 11.78
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol (2004) 7.61
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell (1987) 7.25
AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature (2002) 7.12
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science (2009) 6.96
Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem (2007) 6.92
Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem (1999) 6.67
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe (2008) 6.24
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem (2010) 5.99
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell (2002) 5.14
Retroviral restriction by APOBEC proteins. Nat Rev Immunol (2004) 5.00
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature (2002) 4.89
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci U S A (2003) 4.89
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell (2012) 4.52
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science (1986) 4.04
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A (1994) 3.85
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 3.76
Global landscape of HIV-human protein complexes. Nature (2011) 3.70
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol (2010) 3.61
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol (2006) 3.57
Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol (2004) 3.57
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature (2005) 3.53
Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science (1993) 3.52
RNA hairpins in noncoding regions of human brain and Caenorhabditis elegans mRNA are edited by adenosine deaminases that act on RNA. Proc Natl Acad Sci U S A (2002) 3.41
APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem (2006) 3.30
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem (2004) 3.27
The AID/APOBEC family of nucleic acid mutators. Genome Biol (2008) 3.25
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Constitutive expression of AID leads to tumorigenesis. J Exp Med (2003) 3.16
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nat Immunol (2007) 3.14
Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet (2003) 3.11
Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet (2006) 3.07
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem (2004) 3.01
Effects of retroviruses on host genome function. Annu Rev Genet (2008) 2.96
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem (2006) 2.86
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology (2005) 2.84
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature (2008) 2.80
Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci U S A (1995) 2.80
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology (2004) 2.75
APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem (2004) 2.73
HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem (2005) 2.62
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol (2006) 2.58
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54
DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol (2007) 2.53
G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A (1994) 2.52
Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog (2007) 2.52
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
AID in somatic hypermutation and class switch recombination. Curr Opin Immunol (2006) 2.48
Pyrimidine and purine biosynthesis and degradation in plants. Annu Rev Plant Biol (2006) 2.48
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res (2005) 2.43
AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature (2002) 7.12
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol (2010) 3.61
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol (2004) 3.59
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem (2006) 2.86
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature (2008) 2.80
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem (2005) 2.62
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Immunity through DNA deamination. Trends Biochem Sci (2003) 2.39
Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res (2012) 2.29
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol (2008) 1.85
Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (2010) 1.65
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol (2009) 1.62
Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Lett (2007) 1.62
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol (2008) 1.51
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem (2010) 1.38
Pillars article: AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 2002. 418: 99-103. J Immunol (2015) 1.38
Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem (2012) 1.38
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A (2007) 1.35
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol (2012) 1.28
Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife (2013) 1.28
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol (2011) 1.25
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
APOBEC3B and AID have similar nuclear import mechanisms. J Mol Biol (2012) 1.22
Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev (2006) 1.21
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood (2012) 1.15
Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure (2013) 1.13
MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells. Mol Immunol (2005) 1.13
Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol (2010) 1.12
AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res (2009) 1.09
Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle (2013) 1.07
Competition of Escherichia coli DNA polymerases I, II and III with DNA Pol IV in stressed cells. PLoS One (2010) 1.07
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer (2014) 1.07
The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One (2007) 1.04
HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces. AIDS Res Hum Retroviruses (2012) 1.03
Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G. PLoS Pathog (2012) 1.02
Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry (2012) 1.00
Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem (2013) 0.99
Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J Biol Chem (2011) 0.98
The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. J Mol Biol (2013) 0.97
Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol (2008) 0.96
Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J Virol (2009) 0.95
DNA-dependent protein kinase inhibits AID-induced antibody gene conversion. PLoS Biol (2007) 0.94
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res (2015) 0.93
Unique DNA repair gene variations and potential associations with the primary antibody deficiency syndromes IgAD and CVID. PLoS One (2010) 0.93
Directed DNA deamination by AID/APOBEC3 in immunity. Curr Biol (2006) 0.91
Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem (2012) 0.90
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. J Struct Biol (2013) 0.88
Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G. J Virol (2013) 0.88
Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virol J (2014) 0.86
Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. J Mol Biol (2013) 0.84
CEM-T4 cells do not lack an APOBEC3G cofactor. PLoS Pathog (2009) 0.82
Dancin' deaminase. Nat Struct Mol Biol (2006) 0.80
The interaction between AID and CIB1 is nonessential for antibody gene diversification by gene conversion or class switch recombination. PLoS One (2010) 0.79
D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B. Virology (2013) 0.78
APOBEC3 inhibits DEAD-END function to regulate microRNA activity. BMC Mol Biol (2013) 0.77
Correction: HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation. PLoS Pathog (2017) 0.75